44 k whole human genome expression oligonucleotide microarray (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
44 k whole human genome expression oligonucleotide microarray
44 K Whole Human Genome Expression Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/44+k+whole+human+genome+expression+oligonucleotide+microarray/pm38191557-263-56-53
Average 90 stars, based on 1 article reviews
44 K Whole Human Genome Expression Oligonucleotide Microarray, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/44+k+whole+human+genome+expression+oligonucleotide+microarray/pm38191557-263-56-53
Average 90 stars, based on 1 article reviews
44 k whole human genome expression oligonucleotide microarray - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Expressing:Article Title: Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Article Snippet: .. These samples were obtained at biopsy from differentmetastatic sites including adrenal (n = 1), bone (n = 11), liver (n = 3), lung (n = 2), lymph node (n = 9), prostate (n = 7), and skull base (n = 1). ref. 69 cohort includes CRPC samples obtained at rapid autopsy, profiled on Agilent 44 K Article Title: Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel Article Snippet: .. To study gene expression in metastatic samples, we used the following datasets: [ ] GSE32269, which contains transcriptomic data from 22 primary PCa (hormone-dependent) and 29 metastatic PCa (CRPC) samples, obtained by Affymetrix Human Genome U133A Array; [ ] GSE74685 dataset from Fred Hutchinson Cancer Research Center, which comprises a PCa patient’s cohort with samples from primary ( n = 14) or metastatic ( n = 149) tumors from 63 PCa patients (20 bone metastasis, 21 liver metastasis, 69 lymph node metastasis, 22 lung metastasis and 17 other metastasis), with complete Agilent 44 K Microarray:Article Title: Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Article Snippet: .. These samples were obtained at biopsy from differentmetastatic sites including adrenal (n = 1), bone (n = 11), liver (n = 3), lung (n = 2), lymph node (n = 9), prostate (n = 7), and skull base (n = 1). ref. 69 cohort includes CRPC samples obtained at rapid autopsy, profiled on Agilent 44 K Article Title: Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel Article Snippet: .. To study gene expression in metastatic samples, we used the following datasets: [ ] GSE32269, which contains transcriptomic data from 22 primary PCa (hormone-dependent) and 29 metastatic PCa (CRPC) samples, obtained by Affymetrix Human Genome U133A Array; [ ] GSE74685 dataset from Fred Hutchinson Cancer Research Center, which comprises a PCa patient’s cohort with samples from primary ( n = 14) or metastatic ( n = 149) tumors from 63 PCa patients (20 bone metastasis, 21 liver metastasis, 69 lymph node metastasis, 22 lung metastasis and 17 other metastasis), with complete Agilent 44 K Gene Expression:Article Title: Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel Article Snippet: .. To study gene expression in metastatic samples, we used the following datasets: [ ] GSE32269, which contains transcriptomic data from 22 primary PCa (hormone-dependent) and 29 metastatic PCa (CRPC) samples, obtained by Affymetrix Human Genome U133A Array; [ ] GSE74685 dataset from Fred Hutchinson Cancer Research Center, which comprises a PCa patient’s cohort with samples from primary ( n = 14) or metastatic ( n = 149) tumors from 63 PCa patients (20 bone metastasis, 21 liver metastasis, 69 lymph node metastasis, 22 lung metastasis and 17 other metastasis), with complete Agilent 44 K |